These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 27619773)
1. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Lawrenz B; Beligotti F; Engelmann N; Gates D; Fatemi HM Hum Reprod; 2016 Nov; 31(11):2554-2560. PubMed ID: 27619773 [TBL] [Abstract][Full Text] [Related]
2. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174 [TBL] [Abstract][Full Text] [Related]
3. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles. Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360 [TBL] [Abstract][Full Text] [Related]
4. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study. Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196 [TBL] [Abstract][Full Text] [Related]
5. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435 [TBL] [Abstract][Full Text] [Related]
6. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589 [TBL] [Abstract][Full Text] [Related]
7. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535 [TBL] [Abstract][Full Text] [Related]
8. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial. Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ; Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613 [TBL] [Abstract][Full Text] [Related]
9. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Vuong TN; Phung HT; Ho MT Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882 [TBL] [Abstract][Full Text] [Related]
10. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159 [TBL] [Abstract][Full Text] [Related]
11. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B; Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273 [TBL] [Abstract][Full Text] [Related]
12. Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Broekmans FJ; Verweij PJ; Eijkemans MJ; Mannaerts BM; Witjes H Hum Reprod; 2014 Aug; 29(8):1688-97. PubMed ID: 24903202 [TBL] [Abstract][Full Text] [Related]
13. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial. Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188 [TBL] [Abstract][Full Text] [Related]
14. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC; Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043 [TBL] [Abstract][Full Text] [Related]
16. The effect of polymorphisms in FSHR gene on late follicular phase progesterone and estradiol serum levels in predicted normoresponders. Neves AR; Vuong NL; Blockeel C; Garcia S; Alviggi C; Spits C; Ma PQM; Ho MT; Tournaye H; Polyzos NP Hum Reprod; 2022 Oct; 37(11):2646-2654. PubMed ID: 36069495 [TBL] [Abstract][Full Text] [Related]
17. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles. Vidal MDM; Martínez F; Rodríguez I; Polyzos NP Hum Reprod; 2024 May; 39(5):1098-1104. PubMed ID: 38498835 [TBL] [Abstract][Full Text] [Related]
18. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065 [TBL] [Abstract][Full Text] [Related]
19. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles. Martinez F; Clua E; Roca M; Garcia S; Polyzos NP Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092 [TBL] [Abstract][Full Text] [Related]
20. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve. Friis Wang N; Bogstad JW; Pors SE; Petersen MR; Pinborg A; Yding Andersen C; Løssl K Hum Reprod; 2023 Apr; 38(4):716-725. PubMed ID: 36721920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]